The Precision Peptide Company reports developments around advanced peptide formulations and delivery systems for the wellness market. Recurring updates include the Amino Innovations platform, needle-free transdermal peptide patches, the BPC-157 patch, the Immune Defense Patch formulated with Thymosin Alpha-1, and broader work on oral and transdermal delivery technology.
Company news also covers capital and governance actions such as warrant exercises, restricted share units, stock options, debt settlement, material agreements, and commentary on the evolving U.S. regulatory framework for peptide substances. The company describes products manufactured in an approved U.S. facility and distributed across North America.
The Precision Peptide Company (CSE: BPC, OTCQB: PNGAF) announced that seven peptide-based wellness products are now in stock and available for direct purchase at precisionpeptidecompany.com across all 50 U.S. states. The lineup spans capsules, a topical serum and The Recovery Patch, the company’s first transdermal patch product, designed as a needle-free, no-mixing, no-refrigeration format for active individuals.
According to Precision Peptide, products are manufactured in a U.S. facility to cGMP standards and third-party tested for purity, potency and identity. The retail launch follows the company’s new telehealth and compounding infrastructure and is supported by LegitScript Healthcare Merchant Certification, which underpins compliance, consumer-safety, payment-processing and advertising capabilities. The company is also accepting wholesale applications from clinics, gyms, spas and wellness retailers, while GLP-1, Sermorelin and NAD+ protocols are listed as coming soon via its 503A compounding and telehealth pathway, with no set timeline.
On July 23–24, 2026, the FDA’s Pharmacy Compounding Advisory Committee voted in favor of six of seven peptides reviewed for consideration on the 503A Bulks List, including BPC-157, KPV, thymosin beta-4, MOTS-c, semax and epitalon; four of these are used in the company’s existing formulations. Precision Peptide emphasizes that these non-binding recommendations are not FDA approval, that any 503A listing would require separate rulemaking with uncertain timing, and that the 503A Bulks List does not govern its over-the-counter retail products.
The Precision Peptide Company (CSE: BPC, OTCQB: PNGAF) has begun testing its Thymosin Alpha-1 transdermal patch, a consumer wellness product aimed at immune support. Testing, focused on formulation stability and performance, is being conducted in the United States and is targeted for completion in Q3/Q4 2026.
The company believes, based on its review of currently available products, that this could be among the first commercially available Thymosin Alpha-1 transdermal patches. The patch is designed as a portable, needle-free format requiring no mixing or cold storage and is being developed to expand BPC's transdermal portfolio into the immune-support category. The product has not been evaluated by the FDA or Health Canada and is not intended to diagnose, treat, cure, or prevent any disease.
The Precision Peptide Company (CSE: BPC, OTCQB: PNGAF) reports that on July 23, 2026, the FDA’s Pharmacy Compounding Advisory Committee voted 8–6 (with one abstention) to recommend BPC-157 for inclusion on the Section 503A Bulks List and also recommended that BPC-157 and KPV be considered for inclusion on the FDA’s 503A Bulks List.
The company emphasizes that the recommendation is advisory and still subject to final FDA review. It links this regulatory development to its commercialization efforts, noting a 20,000-unit production run of its BPC-157 transdermal patch manufactured and independently tested in the United States. Each patch is formulated to deliver 2 mg of BPC-157, with third-party testing confirming 95.5% chromatographic purity and an actual quantified dose of 2.02 mg per patch, exceeding a ≥95% high-purity benchmark widely recognized in the peptide industry.
The Precision Peptide Company (CSE: BPC, OTCQB: PNGAF) has launched a nationwide direct-to-consumer retail and telehealth website, now accessible in all 50 U.S. states at www.precisionpeptidecompany.com.
The platform creates a unified channel for online purchasing, product education and telehealth consultations, covering oral supplements, topical formulations and differentiated needle-free transdermal peptide patches that require no mixing or cold storage. According to the company, compounded peptide products under its 503A compounding agreement are 100% U.S.-compounded and supported by LegitScript Healthcare Merchant Certification, which underpins compliance, consumer-safety, payment-processing and advertising standards. The infrastructure is designed to align with applicable U.S. legal, HIPAA, telehealth and pharmacy regulations, and to support customer acquisition, repeat purchases, future subscription offerings and continued nationwide expansion.
The Precision Peptide Company (CSE: BPC, OTCQB: PNGAF) announced receipt of its full production run of approximately 20,000 units of its BPC-157 transdermal patch, the company's lead product candidate. This commercial inventory follows a previously announced order and marks a transition from testing and formulation validation toward commercialization.
The Patch is manufactured in the United States and independently tested by a U.S. analytical laboratory. Each patch is formulated to deliver 2 mg of BPC-157, supported by third-party results confirming 95.5% chromatographic purity and a quantified dose of 2.02 mg per patch. The company plans initial commercial release through its website.
The Precision Peptide Company (OTCQB: PNGAF) has launched its consumer-facing telehealth retail website, enabling prescription-based peptide purchases across all 50 U.S. states. The site connects consumers with licensed providers, prescription workflows, and U.S.-based pharmacy fulfillment.
All peptides, including BPC-157, are 100% compounded in the U.S. under a 503A agreement. Supported by LegitScript Healthcare Merchant Certification, the platform is designed to align with applicable U.S. legal, HIPAA, and pharmacy regulations and positions the company for nationwide commercial rollout ahead of anticipated regulatory developments.
The Precision Peptide Company (OTCQB: PNGAF) announced its needle-free Recovery Patch, formulated with BPC-157, will be featured in the June–August 2026 issue of Men's Health magazine.
The product appears in the "Going Strong" showcase, directing readers to precisionpeptidecompany.com ahead of the July 21, 2026 newsstand release.
The Precision Peptide Company (OTCQB: PNGAF, CSE: BPC) announced it has obtained LegitScript Healthcare Merchant Certification, an independent seal recognizing compliance, transparency, and consumer-safety standards.
The certification is recognized by Visa, Mastercard, Google, Microsoft, and Meta, supporting BPC's access to payment processing, online advertising, and its broader e-commerce growth strategy.
The Precision Peptide Company (CSE:BPC, OTCQB:PNGAF) announced the release of a new episode of The Human Upgrade with Dave Asprey featuring its Chief Scientific Officer, Justin Kirkland. The discussion covers peptide quality, U.S.-based synthesis, manufacturing residues, and the company’s work on needle-free microneedle patch delivery.
The episode is available on Apple Podcasts, Spotify, YouTube, and daveasprey.com.
The Precision Peptide Company (CSE:BPC, OTCQB:PNGAF) signed an agreement with a U.S.-based prescription telehealth and infrastructure partner to support compliant prescribing, fulfillment, and delivery of its peptide products.
This builds on its 503A U.S. sterile compounding deal and creates nationwide prescription-based peptide access ahead of the July 23, 2026 PCAC review of BPC-157 and other peptides.